

## ***Publication of the 2021 Annual Financial Report***

**Paris (France), April 28, 2022 – 6.00 pm CEST - Onxeo S.A.** (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), hereafter “**Onxeo**” or the “**Company**”, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announced the publication of the Company’s 2020 annual financial report.

The 2021 annual financial report is available to the public [on the Company’s website](#).

\*\*\*

### **About Onxeo**

**Onxeo** (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

**platON** is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline.

**AsiDNA**, the first compound from platON, is a highly differentiated, clinical-stage first-in-call candidate in the field of DNA damage response (DDR) applied to oncology. Its decoy and agonist mechanism acting upstream of multiple DDR pathways results in distinctive antitumor properties, including the ability to prevent or abrogate tumor resistance to targeted therapies such as PARP inhibitors and strong synergy with tumor DNA-damaging agents such as radio-chemotherapy. AsiDNA is currently in combination clinical trials in difficult-to-treat solid tumors.

**OX401** is a new drug candidate from platON, designed to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is currently being optimized and is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.

**For further information, please visit [www.onxeo.com](http://www.onxeo.com).**

### **Forward looking statements**

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the risk factors described in the most recent Company’s registration document or in any other periodic financial report and in any other press release, which are available free of charge on the websites of the Company Group ([www.onxeo.com](http://www.onxeo.com)) and/or the AMF ([www.amf-france.org](http://www.amf-france.org)).



## Contacts

### Onxeo

Valerie Leroy,  
Investor Relations

[investors@onxeo.com](mailto:investors@onxeo.com)

+33 1 45 58 76 00

### Media Relations

Arthur Rouillé  
NewCap

[onxeo@newcap.eu](mailto:onxeo@newcap.eu)

+33 1 44 71 94 98

### Investor Relations / Strategic Communication

Dušan Orešanský / Emmanuel Huynh  
NewCap

[onxeo@newcap.eu](mailto:onxeo@newcap.eu)

+33 1 44 71 94 92

### Certified Adviser for Nasdaq First North

Kapital Partner

[www.kapitalpartner.dk](http://www.kapitalpartner.dk)

[info@kapitalpartner.dk](mailto:info@kapitalpartner.dk)

+45 89 88 78 46